Immunotherapy plus targeted therapy for HR+/HER2-low breast cancer before surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding a new immunotherapy drug (adebrelimab) and a targeted therapy (T-DXd) to standard chemotherapy works better than chemotherapy alone for early-stage HR+/HER2-low breast cancer before surgery. It aims to shrink the tumor and reduce the chance of cancer coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have early-stage breast cancer (stage T1c-T4, N0-N2) that is hormone receptor positive (HR+) and HER2 low (score 1+ or 2+ with negative FISH test).
- You are able to do most daily activities without help (ECOG score 0-1).
- You have enough healthy organ function (kidneys, liver, blood counts) to handle chemotherapy.
- You have not had any previous cancer treatment (like chemo, radiation, or immunotherapy) for this breast cancer.
- You have not had serious lung or heart problems, or other major illnesses that would make the trial risky.
- If you are premenopausal, you agree to use effective birth control during the study and for 7 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
This trial tests a combination of two drugs (SHR-A1811 and Adebrelimab) given before surgery to women with a certain type of breast cancer that is hormone receptor (HR) negative or low and HER2 low. The goal is to see if this treatment can shrink the tumor before surgery.
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.